Context: Insulin can be prescribed as a monotherapy or a combined therapy with other anti-diabetic medications. In this narrative review, the authors aimed to gather data related to comparison of insulin monotherapy versus combination of insulin and other anti-diabetic treatments with regards to different outcome measures in type 2 diabetes. Evidence Acquisition: This study searched and focused on the most recently published systematic reviews and their references investigating issues related to the primary aim. Results: The current data available on this topic is heterogeneous and suffers from low quality with respect to most combination treatments. Considering the efficacy and safety of combination therapy of insulin with older hypoglycemic agents, in general metformin and pioglitazone have the best and worst profiles, respectively. Compared to insulin monotherapy, combination of insulin and metformin is associated with better glycemic control, reduced daily insulin dose, less hypoglycemia, and weight gain; combination of insulin and pioglitazone results in greater hypoglycemia and weight gain and is associated with increased risk of edema and heart failure. Regarding sulphonylurea, there is some concern regarding hypoglycemia and weight gain. Addition of dipeptidyl peptidase-4 inhibitors to insulin seems to be beneficial with respect to glycemic control without any significant adverse effects. New drugs, including glucagon-like peptide-1 agonists and sodium glucose co-transporter 2 inhibitors, have acceptable profiles with significant benefits regarding weight reduction when added on insulin therapy. Conclusions: Considering the quality and longevity of evidence, compared to insulin monotherapy, insulin combined with metformin and pioglitazone has the best and worst profiles, respectively. New anti-diabetic medications have acceptable profiles yet are expensive. It is important for clinicians to meticulously weigh the advantages of combination therapy against the possible adverse effects with each drug class in every patient, individually. Moreover, consideration of patient-important outcomes resulting from vascular complications of DM has been emphasized to be incorporated in diabetes care protocols (4) and should be acknowledged in management strategies of patients with diabetes.
Context
Type 2 diabetes mellitus (T2DM) is a progressive disease characterized by worsening pathophysiology. With currently available anti-diabetic therapies, most of them not being disease modifying, pancreatic β-cell mass and function decrease over time (1) , and the usual course of therapeutic approach for patients with T2DM is sequential addition of hypoglycemic agents with different mechanisms of action followed by insulin therapy (2) .
Insulin can be prescribed as a monotherapy or a combined therapy with other anti-diabetic medications. A desired diabetes treatment protocol includes use of medications that in parallel with optimal glycemic control, do not have significant adverse effects; two of these adverse effects, hypoglycemia and weight gain, are amongst important barriers of insulin initiation or intensification (3).
Moreover, consideration of patient-important outcomes resulting from vascular complications of DM has been emphasized to be incorporated in diabetes care protocols (4) and should be acknowledged in management strategies of patients with diabetes.
Until now, two Cochrane systematic reviews regarding comparison of insulin monotherapy versus insulin combined with oral hypoglycemic agents have been con-new anti-diabetic therapies, including Sodium glucose co-transporter 2 (SGLT2) inhibitors and injectable hypoglycemic agents other than insulin, i.e. glucagon like peptide 1 (GLP-1) agonists.
In this narrative review, the authors aimed to gather data related to comparison of insulin monotherapy versus combinations of insulin and other anti-diabetes treatments with regards to different outcome measures, including a) glycemic control, b) required daily insulin dose, c) adverse events, d) diabetes-related morbidity, e) healthrelated quality of life and patient satisfaction, and f) mortality.
Evidence Acquisition
The terms (insulin) AND (hypoglycemic) OR (antidiabetic) OR "glucose-lowering" OR (sulphonylurea) OR (metformin) OR (pioglitazone) OR "DPP-4 inhibitor" OR "DPP4
inhibitor" OR "GLP-1 agonist" OR "GLP-1 receptor agonist"
OR "SGLT2 inhibitor" were used to search review articles in Pubmed, Scopus, and Cochrane library up to 01 September 2017. The researchers focused on the most recently published systematic reviews and their references investigating issues related to the primary aim. With regards to the scarse data available on the comparison of insulin monotherapy versus combinations of insulin with new medication classes, addition of these drugs to any insulinbased therapies has been considered.
Results

Insulin Monotherapy Versus Insulin Plus Sulphonylurea
In Recently, the Cochrane group published a systematic review with the aim of assessing the effects of addition of oral hypoglycemic agents to insulin monotherapy (6) . The main difference between this review protocol and older ones was the manner, according to which they included trials with patients already on insulin therapy. Primary outcomes included all-cause mortality, diabetes-related morbidity, and adverse events. With regards to different sulphonylureas, including glibenclamide, glipizide, tolazamide, gliclazide, and glimepiride, 17 trials (26-41) had low quality evidence, and compared combination therapy with insulin monotherapy; mortality and morbidity were not evaluated in any trials. Regarding patient satisfaction, results of the Switch pilot study showed no differences between insulin-glimepiride therapy and insulin monotherapy (31). The main findings of analyses related to other outcomes have been depicted in Table 1 .
Taken together, findings of 2 Cochrane systematic reviews mentioned above indicate that the additional effect of the combination of insulin with sulphonylurea on glycemic control in insulin-naive patients seems to be small; regarding the effectiveness of sulphonylureainsulin combination compared to insulin monotherapy, it is important to note whether patients are insulin-naive or already on insulin therapy.
Insulin Monotherapy Versus Insulin Plus Metformin
In 2012, Hemmingsen et al. reported results of a metaanalysis on 23 RCTs (24, 42-52) (53-67) with 2,117 participants, investigating the efficacy and safety of metformin and insulin versus insulin therapy alone (68). Primary outcomes were all cause mortality and cardiovascular mortality. Secondary outcomes were macrovascular and microvascular 
Insulin Monotherapy Versus Insulin Plus Pioglitazone
According to Vos et al.'s systematic review (6) , data for comparison of the efficacy and safety of combined insulinpioglitazone therapy with insulin monotherapy, from 3 trials (69-71), was rated as low-quality evidence. Regarding glycemic control, it was not possible to run a meta-analysis.
Overall glycemic control was comparable in the 2 groups.
Insulin plus pioglitazone therapy was associated with both increase in mild to moderate hypoglycemic episodes and weight gain (3.8 kg [95% CI 3.0 to 4.6]) and a small reduction in total daily insulin requirement compared to insulin alone; more cases of dose-dependent edema (69, 70) and heart failure (69) were also observed.
Insulin Monotherapy Versus Insulin Plus Dipeptidyl
Peptidase-4 (DPP-4) Inhibitors
Based on a recent Cochrane review (6), low-quality evi- 
Insulin Plus GLP-1 Agonists
Findings 
Conclusions
Current data available on this topic is heterogeneous and suffers from low quality with respect to most combination treatments. Based on the findings presented in Table   2 , considering the efficacy and safety of combination therapy of insulin with older hypoglycemic agents, generally, metformin and pioglitazone have the best and worst profiles, respectively. Compared with insulin monotherapy, combination of insulin and metformin is associated with better glycemic control, reduced daily insulin dose, less hypoglycemia, and weight gain; combination of insulin and pioglitazone results in greater hypoglycemia and weight gain and has increased risk of edema and heart failure. Regarding sulphonylurea, there is some concern about hypoglycemia and weight gain. Addition of dipeptidyl peptidase inhibitors to insulin seems to be beneficial with respect to glycemic control without any significant adverse effects. New drugs, including glucagon like peptide-1 agonists and sodium glucose co-transporter 2 inhibitors, have acceptable profiles with significant benefits regarding weight reduction when added on insulin therapy.
It should be noted that this research did not undertake a systematic search on this subject. Although qualified systematic reviews included in the review covered most related evidence, there is certainly concern regarding missing available evidence related to the topic.
In conclusion, when considering a patient receiving 
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